An examination of publicly traded genomics companies reveals they have captured the imaginations of investors, whose enthusiasm has translated into substantial gains for the firms' stock prices since they debuted in the capital markets.

This dynamic niche of biotechnology is analyzed and the key players are profiled in a new report, the BioWorld 1997 Genomics Review: Companies Leading The Revolution.

The report includes:

* profiles of public and private genomics companies

* details of nearly 200 collaborations

* a complete listing of human disease genes and organism genomes that have been decoded.

To purchase this new report, call (800) 879-8790 or (404) 262-5526.